Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: A radiographic study in 358 de novo human glioblastomas

Ellingson, Benjamin M.; Cloughesy, Timothy F.; Pope, Whitney B.; Zaw, Taryar; Phillips, Heidi S.; Lalezari, Shadi; Nghiemphu, Phioanh L.; Ibrahim, Hassana; Naeini, Kourosh Manouchehri; Harris, Robert J.; Lai, Albert

doi:10.1016/j.neuroimage.2011.09.076

Cited by 116 publications

(108 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…10 These findings were also consistent with those in the current study with more patients. Hemispheric asymmetry in brain structures is well documented, 21,22 particularly in the temporal lobe.…”

Section: Atlas Of Mgmt Promoter Methylation Detects Temporal Lobe Asysupporting

confidence: 92%

“…10 ADIFFI analysis of glioblastomas based on MGMT promoter methylation status identified a cluster in the right temporal lobe as most frequently associated with MGMT promoter unmethylated tumors and a similar cluster in the left temporal lobe most frequently associated with MGMT promoter methylated tumors (a in Fig 4A), similar to previous data. 10 MGMT promoter methylated tumors had a lower volume of contrast enhancement (Fig 4C; t test, P ϭ .038) and T2/FLAIR hyperintensity (Fig 4C; t test, P ϭ .004) compared with unmethylated tumors. Four hundred patients with glioblastoma had IDH1 mutation status information available, for which 8.5% of glioblastomas were IDH1-mutated.…”

Section: Mgmt Promoter Methylation and Idh1 Mutationsupporting

confidence: 88%

“…Subsets of these patients were used in other studies. 7,10,11 The extent of resection was noted for the initial surgery. Overall survival was defined as the time from initial pathologic diagnosis until death.…”

Section: Patientsmentioning

confidence: 99%

“…10,12 Briefly, the general regions of tumor on T2/FLAIR and T1ϩC images were first defined manually. Then, T2/FLAIR and T1ϩC images were thresholded by using an empiric threshold combined with a region-growing algorithm confined to the manually defined ROIs in the first step.…”

Section: Roismentioning

confidence: 99%

“…Centralized review of progression-free survival was performed for all patients with available scans as previously described. 7,10 The date of death was used as the data of progression if the patient had a stable scan finding Ͻ2 months before death.…”

Section: Time To Progression For Radiochemotherapy Interventional Phementioning

confidence: 99%

See 4 more Smart Citations

Probabilistic Radiographic Atlas of Glioblastoma Phenotypes

Ellingson¹,

Lai

Harris³

et al. 2012

AJNR Am J Neuroradiol

194

156

View full text Add to dashboard Cite

BACKGROUND AND PURPOSE:Tumor location is a significant prognostic factor in glioblastoma, which may reflect the genetic profile of tumor precursor cells. The purpose of the current study was to construct and analyze probabilistic radiographic atlases reflecting preoperative tumor locations and corresponding demographic, "-omic," and interventional phenotypes to provide insight into potential niche locations of glioblastoma cells of origin.

show abstract

Section: Atlas Of Mgmt Promoter Methylation Detects Temporal Lobe Asysupporting

confidence: 92%

Section: Mgmt Promoter Methylation and Idh1 Mutationsupporting

confidence: 88%

Section: Patientsmentioning

confidence: 99%

Section: Roismentioning

confidence: 99%

Section: Time To Progression For Radiochemotherapy Interventional Phementioning

confidence: 99%

See 3 more Smart Citations

Probabilistic Radiographic Atlas of Glioblastoma Phenotypes

Ellingson¹,

Lai

Harris³

et al. 2012

AJNR Am J Neuroradiol

194

156

View full text Add to dashboard Cite

show abstract

Prognostic value of test(s) for O6-methylguanine–DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide

McAleenan

Kelly

Spiga

et al. 2021

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

Contrast‐enhancing tumor growth dynamics of preoperative, treatment‐naive human glioblastoma

Ellingson

Nguyen

Lai

et al. 2016

Cancer

Self Cite

View full text Add to dashboard Cite

BACKGROUND:Little is known about the natural growth characteristics of untreated glioblastoma before surgical or therapeutic intervention, because patients are rapidly treated after preliminary radiographic diagnosis. Understanding the growth characteristics of uninhibited human glioblastoma may be useful for characterizing changes in response to therapy. Thus, the objective of the current study was to explore tumor growth dynamics in a cohort of patients with untreated glioblastoma before surgical or therapeutic intervention. METHODS: Ninety-five patients with glioblastoma who had measurable enhancing disease on >2 magnetic resonance imaging scans before surgery were identified. Tumor growth rates were quantified in 4 different ways (the percentage change per day, the absolute rate of change per day, the estimated volumetric doubling time, and the radial expansion rate) using 3 different approaches (bidirectional product, enhancing disease, and total lesion volume). RESULTS: The median volumetric doubling time was 21.1 days, the percentage change in tumor volume was 2.1% per day, and the rate of change in total lesion volume was 0.18 cc per day. The length of follow-up between magnetic resonance imaging examinations should be >28 days to detect progressive disease with high specificity. Small initial tumor sizes (<3 cm in greatest dimension) are biased toward a large percentage change at follow-up. CONCLUSIONS: Presurgical, treatment-naive glioblastoma growth dynamics can be estimated in a variety of ways with similar results. The percentage changes in tumor size and volume depend on baseline tumor size and the time interval between scans.

show abstract

Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: A radiographic study in 358 de novo human glioblastomas

Cited by 116 publications

References 40 publications

Probabilistic Radiographic Atlas of Glioblastoma Phenotypes

Probabilistic Radiographic Atlas of Glioblastoma Phenotypes

Prognostic value of test(s) for O6-methylguanine–DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide

Contrast‐enhancing tumor growth dynamics of preoperative, treatment‐naive human glioblastoma

Contact Info

Product

Resources

About